NDAORALTABLETPriority Review
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
17
Data completeness
6/8 — Strong
Priority Review
LAZCLUZE (lazertinib) by Johnson & Johnson is kinase inhibitors [moa]. Approved for kinase inhibitor [epc]. First approved in 2024.
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LAZCLUZE (lazertinib) is an oral small-molecule kinase inhibitor approved by the FDA on August 19, 2024. It targets specific kinase pathways implicated in oncologic and hematologic malignancies. The drug is indicated for patients requiring targeted kinase inhibition therapy.
Growth15.1 years to LOE
Early-stage product in growth phase with Johnson & Johnson backing; commercial infrastructure still ramping and team expansion likely in sales and marketing roles.
Mechanism of Action
Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (17)
A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC
Started Jul 2026
68 enrolled
Carcinoma, Non-Small-Cell Lung
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Started Dec 2024
480 enrolled
Carcinoma, Non-Small-Cell Lung
Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
Started Feb 2024
305 enrolled
Carcinoma, Non-Small-Cell Lung
A Study of Lazertinib (JNJ-73841937) Tablet in Healthy Adult Participants
Started May 2023
72 enrolled
Healthy
Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations
Started May 2023
54 enrolled
Metastatic Non-small Cell Lung Cancers
Worked on LAZCLUZE at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.